Antitumour activity of mitoxantrone-loaded chitosan microspheres against Ehrlich ascites carcinoma

Simple item page
dc.contributor.authorJameela, SR
dc.contributor.authorLatha, PG
dc.contributor.authorSubramoniam, A
dc.contributor.authorJayakrishnan, A
dc.date.accessioned2017-03-10T03:25:32Z
dc.date.available2017-03-10T03:25:32Z
dc.date.issued1996
dc.description.abstractGlutaraldehyde cross-linked chitosan microspheres containing the antineoplastic agent mitoxantrone were prepared and the antitumour activity was evaluated against Ehrlich ascites carcinoma in mice by intraperitoneal injections. The tumour inhibitory effect was followed by monitoring animal survival time and change in body weight for a period of 60 days. While the mean survival time of animals which received 2 mg and 1 mg of free mitoxantrone intraperitoneally was 2.1 and 4.6 days, respectively, animals which received 2 mg mitoxantrone via microspheres showed a mean survival time of 50 days. Five out of 8 animals treated using microspheres lived beyond 60 days. The percentage ratio mean survival time of the treated group divided by the mean survival time of the untreated group for animals treated using mitoxantrone-loaded chitosan microspheres containing 2 mg of the drug was 290 compared with 12.2 for those which received 2 mg of the free drug. The antitumour effect of mitoxantrone-loaded microspheres against Ehrlich ascites carcinoma was much higher than that of doxorubicin-loaded microspheres reported by previous workers. Our data demonstrate the potential of mitoxantrone-loaded chitosan microspheres for sustained drug delivery to minimize drug toxicity and maximize therapeutic efficacy.
dc.identifier.citation48 ,7;685-688en_US
dc.identifier.urihttps://dspace.sctimst.ac.in/handle/123456789/9316
dc.publisherJOURNAL OF PHARMACY AND PHARMACOLOGY
dc.subjectPharmacology & Pharmacy
dc.titleAntitumour activity of mitoxantrone-loaded chitosan microspheres against Ehrlich ascites carcinoma
Files
Collections
Journal Articles